Rare disease focus Target opportunities around hereditary antithrombin deficiency and related coagulation disorders where rEVO Biologics already has a lead product ATryn and ongoing clinical exploration in preeclampsia (PRESERVE-1). Align propositions with specialty pharmacies, rare disease networks, and reimbursement pathways.

Clinical trial expansion Position to support the PRESERVE-1 Phase 3 program and any future indications by offering CRO/CMC/biostudy support, patient recruitment channels, and reimbursement strategy services to accelerate development timelines and market entry.

Strategic partnerships Leverage parent company LFB Biotechnologies' network and potential co-development or distribution agreements to extend reach in specialized markets, while offering enabling services for global supply chain readiness and regulatory alignment.

Biotech enablement Provide technology and service offerings that complement small-scale biopharma needs such as manufacturing scale-up support, quality systems, analytical methods, and digital tooling to optimize production of recombinant Antithrombin and other potential modalities.

Talent & funding signals With a lean team and ongoing clinical programs, identify opportunities in consulting, investigator site networks, and early-stage collaborations that can help accelerate development, regulatory filing, and market access while offering strategic partnerships to fund or co-develop.